Clinical trials: Adebrelimab (SHR-1316), open to volunteers
Locally Advanced Gastric or Gastroesophageal Junction Cancer
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate…
- Trial name
- NCT07522151
- Testing
- Adebrelimab plus S-1 and oxaliplatin, Adebrelimab blank preparation plus S-1 and oxaliplatin.
- Where
- China
- Volunteers
- 874 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Adebrelimab (SHR-1316), XELOX
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric cancer/adenocarcinoma of the gastroesophageal junction.
- Conditions
- Adebrelimab (SHR-1316), XELOX, GC/GEJC
- Trial name
- NCT06506292
- Testing
- Adebrelimab, XELOX
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Limited-stage Small-cell Lung Cancer
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung…
- Trial name
- NCT07798947
- Testing
- SHR-7787 Injection, SHR-1316
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Adebrelimab (SHR-1316), Bevacizumab
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic…
- Conditions
- Adebrelimab (SHR-1316), Bevacizumab, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07543783
- Testing
- Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Esophageal Cancer (EsC)
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled and treated with adebrelimab (SHR-1316) combined…
- Trial name
- NCT06869213
- Testing
- Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Limited Stage Small Cell Lung Cancer
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
To compare the efficiency between surgery and radiotherapy after SHR-1316 (Adebrelimab)and platinum-containing doublet induction therapy for limited-stage small cell lung cancer
- Trial name
- NCT05496166
- Testing
- chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Triple Negative Breast Cancer
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
It is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers…
- Trial name
- NCT07679360
- Testing
- Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cholangiocarcinoma Cancer, Adebrelimab (SHR-1316)
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
Biliary tract malignancies (BTC) are malignant tumors that originate from the epithelium of the bile ducts. Currently, the optimal treatment for biliary tract malignancies is radical surgical resection.
- Trial name
- ACHIEVE (NCT06607276)
- Testing
- Adebrelimab and capecitabine, capecitabine
- Where
- 4 sites in China
- Volunteers
- 122 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Muscular Invasive Bladder Cancer (MIBC)
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of…
- Trial name
- NCT06879145
- Testing
- SHR-A2102；Adebrelimab
- Where
- China
- Volunteers
- 840 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Adebrelimab (SHR-1316), Decitabine
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
Pancreatic cancer is a kind of digestive system tumor with extremely high malignancy and poor prognosis. Although the trend of benefit from immunotherapy in combination with chemotherapy is currently reflected in several…
- Conditions
- Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer
- Trial name
- NCT06454448
- Testing
- Adebrelimab;decitabine;
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Adebrelimab (SHR-1316), NSCLC
Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
This study is a single arm, prospective, multicenter clinical trial, and eligible patients will receive the following treatment regimen: Adebrelimab combined with chemotherapy.The study includes a screening period (from the…
- Conditions
- Adebrelimab (SHR-1316), NSCLC, Chemotherapy
- Trial name
- NCT07035392
- Testing
- Adebrelimab, chemotherapy
- Volunteers
- 32 people
- Sponsor
- Zhangzhou Municipal Hospital
Esophageal Cancer, ESCC
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
This study will evaluate whether two positron emission tomography/computed tomography (PET/CT) scans performed before treatment-68Ga-FAPI and 18F-FDG-can help predict how well patients with resectable, locally advanced thoracic…
- Trial name
- NCT07770672
- Testing
- Retlirafusp Alfa Plus Chemotherapy, Adebrelimab Plus Chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Tan Lijie
Urothelial Carcinoma, Advanced Urothelial Carcinoma
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
This is a multicenter, open-label, Phase II clinical trial to evaluate the efficacy and safety of Trastuzumab Rezetecan (SHR-A1811) or in combination with Adebrelimab (SHR-1316) for HER2-expressing locally advanced or metastatic…
- Conditions
- Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent
- Trial name
- TRAIN-UC-01 (NCT07241793)
- Testing
- Adebrelimab, Trastuzumab Rezetecan
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Non-squamous Non-small Cell Lung Cancer
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations
- Trial name
- NCT06335355
- Testing
- Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin, Camrelizumab + Pemetrexed + Carboplatin, Adebrelimab + Pemetrexed + Carboplatin
- Where
- China
- Volunteers
- 401 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd